



## ORIGINAL ARTICLE

# High expression of CD38 and MHC class II on CD8<sup>+</sup> T cells during severe influenza disease reflects bystander activation and trogocytosis

Xiaoxiao Jia<sup>1</sup>, Brendon Y Chua<sup>1</sup>, Liyen Loh<sup>1</sup>, Marios Koutsakos<sup>1</sup>, Lukasz Kedzierski<sup>1,2</sup>, Moshe Olshansky<sup>3</sup>, William R Heath<sup>1</sup> , So Young Chang<sup>1</sup>, Jianqing Xu<sup>4†</sup>, Zhongfang Wang<sup>1,5†</sup> & Katherine Kedzierska<sup>1†</sup> <sup>1</sup>Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia<sup>2</sup>Faculty of Veterinary and Agricultural Sciences, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC, Australia<sup>3</sup>Department of Microbiology, Monash University, Clayton, VIC, Australia<sup>4</sup>Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Key Laboratory of Medical Molecular Virology of Ministry of Education/Health, Shanghai Medical College, Fudan University, Shanghai, China<sup>5</sup>State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China**Correspondence**

K Kedzierska, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Parkville, VIC 3010, Australia.

E-mail: kkedz@unimelb.edu.au

## †Equal contributors.

Received 31 March 2021;

Revised 19 May and 10 August 2021;

Accepted 10 August 2021

doi: 10.1002/cti2.1336

*Clinical & Translational Immunology*  
2021; 10: e1336**Abstract**

**Objectives.** Although co-expression of CD38 and HLA-DR reflects T-cell activation during viral infections, high and prolonged CD38<sup>+</sup>HLA-DR<sup>+</sup> expression is associated with severe disease. To date, the mechanism underpinning expression of CD38<sup>+</sup>HLA-DR<sup>+</sup> is poorly understood. **Methods.** We used mouse models of influenza A/H9N2, A/H7N9 and A/H3N2 infection to investigate mechanisms underpinning CD38<sup>+</sup>MHC-II<sup>+</sup> phenotype on CD8<sup>+</sup> T cells. To further understand MHC-II trogocytosis on murine CD8<sup>+</sup> T cells as well as the significance behind the scenario, we used adoptively transferred transgenic OT-I CD8<sup>+</sup> T cells and A/H3N2-SIINKEKL infection. **Results.** Analysis of influenza-specific immunodominant D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD8<sup>+</sup> T-cell responses showed that CD38<sup>+</sup>MHC-II<sup>+</sup> co-expression was detected on both virus-specific and bystander CD8<sup>+</sup> T cells, with increased numbers of both CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T-cell populations observed in immune organs including the site of infection during severe viral challenge. OT-I cells adoptively transferred into MHC-II<sup>-/-</sup> mice had no MHC-II after infection, suggesting that MHC-II was acquired via trogocytosis. The detection of CD19 on CD38<sup>+</sup>MHC-II<sup>+</sup> OT-I cells supports the proposition that MHC-II was acquired by trogocytosis sourced from B cells. Co-expression of CD38<sup>+</sup>MHC-II<sup>+</sup> on CD8<sup>+</sup> T cells was needed for optimal recall following secondary infection. **Conclusions.** Overall, our study demonstrates that both virus-specific and bystander CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells are recruited to the site of infection during severe disease, and that MHC-II presence occurs via trogocytosis from antigen-presenting cells. Our findings highlight the importance of the CD38<sup>+</sup>MHC-II<sup>+</sup> phenotype for CD8<sup>+</sup> T-cell recall.

**Keywords:** CD8<sup>+</sup> T cell, influenza A virus, MHC-II, trogocytosis

## INTRODUCTION

Influenza virus infections lead to annual seasonal epidemics that result in 243 000–640 000 deaths globally every year.<sup>1</sup> In 2017 alone, ~9.5 million people were hospitalised with lower respiratory tract influenza infections for a total of 81.5 million hospital days.<sup>2</sup> Furthermore, disease severity and mortality rapidly escalate when a new influenza A virus (IAV) emerges, for which a matching vaccine is unavailable, as exemplified by the catastrophic 1918–1919 H1N1 pandemic and the emergence of avian-derived H5N1 and H7N9 strains in 2003<sup>3</sup> and 2013,<sup>4</sup> respectively. In the absence of neutralising antibodies, the recall of pre-existing broadly cross-reactive memory CD8<sup>+</sup> T cells that recognise conserved peptide epitopes derived from internal viral proteins presented by infected cells can promote recovery against novel influenza A viruses (IAVs) and even different influenza types.<sup>5–7</sup> Activated CD8<sup>+</sup> T cells can kill virus-infected cells via perforin- and granzyme-mediated lysis but also produce cytokines including IFN- $\gamma$  and TNF- $\alpha$ , which render the local environment non-permissive for virus replication and ultimately provide some degree of heterosubtypic protection in the antibody-naïve individuals.

The importance of broadly cross-reactive CD8<sup>+</sup> T-cell responses in mitigating influenza disease severity has been shown during outbreaks caused by the emergence of novel subtypes, including the 2003 H5N1,<sup>8</sup> 2009 pandemic H1N1<sup>7</sup> and 2013 H7N9 strains.<sup>9,10</sup> Our analysis of immune responses in H7N9-infected hospitalised patients in China demonstrated that early proliferation of H7N9-specific CD8<sup>+</sup> T cells contributes to disease resolution and survival, as reflected by mild to moderate clinical scores and early time to discharge from hospital.<sup>9</sup> In particular, we showed that early, transient co-expression of CD38<sup>+</sup> and HLA-DR<sup>+</sup> (MHC-II<sup>+</sup>) on CD8<sup>+</sup> T cells during the early stages of H7N9 infection was strongly associated with patient survival.<sup>10</sup>

Co-expression of CD38, a cyclic ADP ribose hydrolase and cell surface glycoprotein involved in signal transduction, adhesion and calcium signalling,<sup>11</sup> and MHC-II on CD8<sup>+</sup> T cells is recognised as a classical hallmark of activation during viral infections. CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells can be detected transiently at high levels in patients infected with viruses such as Ebola,<sup>12</sup> HCV,<sup>13</sup> HIV,<sup>14,15</sup> Dengue,<sup>16</sup> pandemic H1N1 IAV<sup>17</sup> and more recently SARS-CoV-2<sup>18,19</sup> during the

acute phase of infection. CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells are known for their proliferative capacity, exhibit effector functions such as cytotoxicity and cytokine production<sup>20–22</sup> and typically decrease in frequency following the resolution of infection.<sup>18,21,22</sup> However, in converse prolonged expression and high frequency of CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells can be associated with a loss of effector function, as shown during chronic viral infections.<sup>23,24</sup> Moreover, H7N9-infected patients with fatal disease outcomes displayed high and prolonged expression of CD38<sup>+</sup>MHC-II<sup>+</sup> on CD8<sup>+</sup> T cells, which had minimal capacity to produce IFN- $\gamma$ , thus linking the prominence of CD38<sup>+</sup>MHC-II<sup>+</sup> phenotype to fatal outcomes in severe IAV-mediated pneumonia.<sup>10</sup>

Despite the important role of CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells in viral control, the underlying mechanisms driving their activation and regulation during viral infections are still poorly understood. Here, using our established H7N9 and H3N2 influenza wild-type and transgenic mouse models, we determined how disease severity affected the activation of IAV-specific CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T-cell responses *in vivo* and the antigenic determinants that drive their activation and expansion. Our study also revealed how this population acquires MHC-II from antigen-presenting cells by trogocytosis and revealed superior recall capacity of CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells.

## RESULTS

### H7N9 infection in mice induces CD38<sup>+</sup>MHC-II<sup>+</sup>PD-1<sup>+</sup> activation profiles

Our previous data revealed that patients hospitalised with severe H7N9 influenza had high and prolonged (more than 4 weeks) expression of CD38, MHC-II and PD-1 on CD8<sup>+</sup> T cells.<sup>10</sup> To understand the mechanisms underlying such hyper-activated CD38, MHC-II and PD-1 phenotype, we first verified the recruitment kinetics and specificity of CD38<sup>+</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>PD-1<sup>+</sup> CD8<sup>+</sup> T cells in a mouse model of H7N9 infection in C57BL/6 (B6) mice. To minimise H7N9-induced mortality, B6 mice were first primed intranasally (i.n.) with 10<sup>4</sup> EID<sub>50</sub> of the avirulent strain A/Chicken/Shanghai/F/98 (H9N2) 60 days prior to i.n. challenge with 10<sup>6</sup> PFU of A/Shanghai/4664T/2013 (H7N9) virus (Figure 1a). As expected, the majority of CD38<sup>+</sup>MHC-II<sup>+</sup> or D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD8<sup>+</sup> T cells in MLN and spleen were

CD44<sup>hi</sup> (antigen-experienced), though expression of CD62L, a molecule that mediates trafficking into lymph nodes via high endothelial venules, differed across these two sites (Figure 1b). Overall, ~20% of CD8<sup>+</sup> T cells in the spleen or mediastinal lymph node (MLN) were CD38<sup>+</sup>MHC-II<sup>+</sup> (20.2% for both spleen and MLN) (Figure 1ci and ii, Supplementary figure 1) or CD38<sup>+</sup>PD-1<sup>+</sup> (range 17.8–20.6%) (Supplementary figure 2) on day 10 after H7N9 exposure. Analysis of CD8<sup>+</sup> T-cell responses directed at the immunodominant D<sup>b</sup>NP<sub>366</sub> epitope showed 3- to 5-fold enrichment of D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD8<sup>+</sup> T cells within the CD38<sup>+</sup>MHC-II<sup>+</sup> (Figure 1ci and ii, Supplementary figure 1) or CD38<sup>+</sup>PD-1<sup>+</sup> (Supplementary figures 1 and 2) sets from the spleen and MLN. Such high level of CD38<sup>+</sup>MHC-II<sup>+</sup> or CD38<sup>+</sup>PD-1<sup>+</sup> on tetramer-specific CD8<sup>+</sup> T cells after H7N9 infection in mice supports the observations from H7N9 patients.

As CD8<sup>+</sup> T cells from H7N9-infected hospitalised patients displayed high PD-1 levels, we compared PD-1 expression on H7N9-specific D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells to that on CD38<sup>+</sup>MHC-II<sup>+</sup> or non-CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells. D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells in both the MLN and spleen displayed the highest level of PD-1 (Figure 1d). As expected, PD-1 levels on CD8<sup>+</sup> T cells negative for CD38<sup>+</sup>MHC-II<sup>+</sup> were minimal. Thus, high PD-1<sup>+</sup> expression on D<sup>b</sup>NP<sub>366</sub><sup>+</sup> CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> and CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells confirmed the correlation between high CD38<sup>+</sup>MHC-II<sup>+</sup>PD-1<sup>+</sup> CD8<sup>+</sup> T-cell prevalence and severe disease.

### Recruitment of CD38<sup>+</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup> T cells to the site of infection

To determine how virus load and disease severity affect the recruitment kinetics and phenotype of CD38<sup>+</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>PD-1<sup>+</sup> CD8<sup>+</sup> T cells, we infected B6 mice intranasally with a low (10<sup>2</sup> PFU) or high (10<sup>5</sup> PFU) dose of A/HK/x31 (H3N2; X31) virus (Figure 2a). While comparable virus replication kinetics were observed at day 3, 5, 7 and 10 after infection (Figure 2b), the high dose caused more severe disease, as evidenced by significantly greater body weight loss between day 3 and day 7 ( $P < 0.001$ ) (Figure 2c), and increased lethality ( $P = 0.003$ ) (Figure 2d) as well as excessive inflammation in the lung (Figure 2e). The 10<sup>5</sup> PFU X31 virus challenge was associated with more rapid acquisition of a PD-1<sup>hi</sup> phenotype ( $P < 0.05$  on day 7) on D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD8<sup>+</sup> T cells (Supplementary figure 3a, b), reflecting the


pattern found previously for H7N9-infected mice and patients who succumbed to H7N9 disease.

As expected, both CD38<sup>+</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>PD-1<sup>+</sup> CD8<sup>+</sup> T cells were upregulated during viral challenge and then decreased along with recovery (Figure 2fi, Supplementary figure 3c). These kinetics were also confirmed on adoptively transferred OT-I cells following influenza A virus infection (Supplementary figure 4). Although cell numbers for all CD38<sup>+</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>PD-1<sup>+</sup> CD8<sup>+</sup> T cells in the regional MLN were comparable from day 5 and beyond (Figure 2fi, Supplementary figure 3c), only a small population of cells (11.8%) were D<sup>b</sup>NP<sub>366</sub><sup>+</sup> (Figure 2fii, Supplementary figure 3c) within CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells (peak on day 10) and (17.3%) within CD38<sup>+</sup>PD-1<sup>+</sup> CD8<sup>+</sup> T cells (peak on day 16), indicating that the majority of CD38<sup>+</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>PD-1<sup>+</sup> CD8<sup>+</sup> T cells recruited during severe influenza disease were tetramer-negative. Furthermore, CD38<sup>+</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>PD-1<sup>+</sup> CD8<sup>+</sup> T cells increased substantially at day 7 at the site of infection (BAL) following the high-dose challenge (Figures 2fi and 3, Supplementary figure 3c), while the IAV-specific CD8<sup>+</sup> T-cell responses peaked 3 days later (Figures 2fii, and 3, Supplementary figure 3c) and at comparable numbers for both (10<sup>5</sup> and 10<sup>2</sup> PFU) groups.


Thus, as a substantially greater number of CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells was found in comparison to tetramer-specific D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD8<sup>+</sup> and D<sup>b</sup>PA<sub>224</sub><sup>+</sup>CD8<sup>+</sup> T cells (constituting > 80% of influenza-specific CD8<sup>+</sup> T cells<sup>25</sup>), our findings suggest that a large proportion of CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cell are “bystander” rather than epitope-specific CD8<sup>+</sup> T cells. Together, these data suggest that D<sup>b</sup>NP<sub>366</sub> tetramer-negative CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells, many of which numerically will not be virus-specific, extravasate into the lung prior to recruitment of the majority of antigen-specific cells. Whether this is a consequence or a cause of more severe inflammation and pathology is currently unclear.

### Murine CD8<sup>+</sup> T cells utilise trogocytosis to acquire MHC-II molecule


As expression of the *H2-Ab* (*MHC-II*) gene at the transcriptional level depends on the transcription factor *CIITA*,<sup>26,27</sup> and murine CD8<sup>+</sup> T cells lack intrinsically expressed *CIITA*,<sup>28</sup> we further investigated how murine CD8<sup>+</sup> T cells acquire expression of MHC-II. We utilised a transgenic OT-I mouse model in the influenza setting. OT-I CD8<sup>+</sup> T cells contain a TCRαβ specific for the K<sup>b</sup>OVA<sub>257–264</sub> (OVA; SIINFEKL) epitope, which



**Figure 1.** H7N9 infection in mice induces CD38<sup>+</sup>MHC-II<sup>+</sup>PD-1<sup>+</sup> activation profiles. **(a)** C57BL/6 mice ( $n = 5$ ) were infected i.n. with H9N2 (A/Chicken/Shanghai/F/98) ( $10^4$  EID50) virus and challenged i.n. at 60 d.p.i. with H7N9 (A/Shanghai/4664T/2013) ( $10^6$  PFU) virus. Spleens and MLNs were harvested 10 days after H7N9 challenge and phenotype of CD8<sup>+</sup> T cells analysed. **(b)** (i) Representative dot plots and (ii) frequencies of CD62L and CD44 expression within CD8<sup>+</sup>, CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> and D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD8<sup>+</sup> T cell populations are shown. **(c)** (i) Representative dot plots and (ii) frequencies of CD38<sup>+</sup>MHC-II<sup>+</sup> within CD8<sup>+</sup> and D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD8<sup>+</sup> T cell populations. **(d)** The expression of PD-1 on D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cell, CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cell and non-CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cell populations from each animal is depicted as (i) histograms and (ii) mean fluorescence intensity (MFI). The experiment was performed one time. Statistical analysis was performed using the Tukey's multiple comparisons test.



**Figure 2.** H3N2 viral dose affects kinetics of CD38<sup>+</sup>MHC-II<sup>+</sup> at the site of infection. **(a)** C57BL/6 mice were infected i.n. with HKx31 (H3N2) at either a high ( $10^5$  PFU) or low ( $10^2$  PFU) viral dose ( $n = 5$ /group). **(b)** At various days post-infection (d.p.i.), lung viral titres were determined in MDCK plaque assays. Each symbols denotes an individual mouse and the mean ( $\pm$  SD) is shown for each group. Mice were also monitored daily after infection for **(c)** weight loss and **(d)** survival (mice were humanely culled when a weight loss of  $> 20\%$  of their pre-experimental body weight was observed over a 2-day period and accompanied by clinical signs of disease, or when a weight loss of  $> 25\%$  of their pre-experimental body weight occurred). **(e)** Lung homogenates were assayed by cytometric bead array to determine the cumulative amount of total cytokines present and the amounts of each cytokine. **(f)** Numbers of (i) total CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells, (ii) D<sup>b</sup>NP<sub>366</sub> tetramer-specific CD8<sup>+</sup> T cells and D<sup>b</sup>NP<sub>366</sub> tetramer-specific CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells in MLN, BAL and spleen at various time-points after infection. The experiment was performed twice. Statistical analysis comparing total cytokines was performed using Sidak's multiple comparisons test. Statistical analysis comparing survival rate was performed using the Log-rank (Mantel-Cox) test. Statistical analysis comparing original body weight and individual cytokines was performed using the unpaired *t*-test (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ).




**Figure 3.** Early recruitment of tetramer-negative CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells to the site infection with a high viral dose of H3N2. B6 mice were infected with HKx31 (H3N2) at either a high (10<sup>5</sup> PFU) or low (10<sup>2</sup> PFU) dose i.n.. At day 7 and day 10 after infection, BAL, spleen and MLN lymphocytes were stained with D<sup>b</sup>NP<sub>366</sub> and D<sup>b</sup>PA<sub>224</sub> tetramers and anti-CD8 antibody, combined with a phenotyping panel for CD38 and I-A<sup>b</sup> (MHC-II). Numbers of CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells, D<sup>b</sup>NP<sub>366</sub><sup>+</sup>CD8<sup>+</sup> and D<sup>b</sup>PA<sub>224</sub><sup>+</sup>CD8<sup>+</sup> T cells are shown in MLN, BAL and spleen at day 7 and day 10 after infection (*n* = 5 mice). The experiment was performed twice. Statistical analysis was performed using Sidak's multiple comparisons test.

proliferate after infection with influenza-OVA virus (with SIINFEKL engineered into the neuraminidase stalk).<sup>29</sup> We adoptively transferred naïve OT-I CD8<sup>+</sup> T cells into MHC-II<sup>-/-</sup> or C57BL/6 wild-type mice prior to X31-OVA infection (Figure 4a). Greater body weight loss (5%) in MHC-II<sup>-/-</sup> mice was observed compared to wild-type mice particularly at 3–5 days post-infection (Figure 4b), indicating that lack of MHC-II expression leads to perturbed immune responses and increased disease severity. When we analysed the expansion of OT-I cells (Figure 4c) by frequency (Figure 4d) or number (Figure 4e) of the total CD8<sup>+</sup> T cell pool, we observed similar numbers in BAL, MLNs and spleens of both WT

and MHC-II<sup>-/-</sup> mice. As there were also no differences in the combined total number of OT-I cells from these organs of each mouse (Figure 4f), this indicates that OT-I cells proliferate to the same extent in both WT and MHC-II<sup>-/-</sup> mice.

Analysis of MHC-II presence on OT-I cells in BAL, MLNs and spleens of MHC-II<sup>-/-</sup> or B6 mice showed that MHC-II expression was only limited to OT-I cells transferred into B6 mice and absent in those transferred into MHC-II<sup>-/-</sup> mice (Figure 5a and b). This observation extended to CD38<sup>+</sup> OT-I cells, thus indicating that murine CD8<sup>+</sup> T cells do not intrinsically express MHC-II but acquire it from other cells during influenza virus infection.




**Figure 4.** Similar OT-I T-cell proliferation in C57BL/6 and MHC-II<sup>-/-</sup> mice after IAV infection. **(a)** C57BL/6 and MHC-II<sup>-/-</sup> mice ( $n = 4$  or  $5$ /group) received  $10^4$  OT-I T cells via the i.v. route 24 h prior to infection. Mice were subsequently infected with  $10^4$  PFU of X31-OVA (H3N2) and BAL, MLN and spleen were harvested at 8 d.p.i. **(b)** Mice were monitored daily during the course of infection for weight loss before OT-I T-cell populations from each organ was enumerated. **(c)** Representative dot plots of CD45.1<sup>+</sup>TCRVα2<sup>+</sup> OT-I T cells within the CD8<sup>+</sup> T cell pool in the MLN. **(d)** Percentages, **(e)** numbers of OT-I T cells in each different organ and **(f)** as a cumulative total. The experiment was performed two times. Statistical analysis comparing original body weight was performed using the unpaired *t*-test (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ).

To determine how transferred OT-I cells could have acquired MHC-II, we stained OT-I cells in influenza-infected mice for markers associated with antigen presentation, including CD19 to represent B cells and CD11c as a surrogate DC and macrophage marker.<sup>30</sup> In BAL, MLN and spleen, CD11c<sup>+</sup> OT-I cells were consistently detected on both CD38<sup>-</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>MHC-II<sup>+</sup> populations in the BAL (mean 11.7% and 31.4%) as well as the MLN (mean 20.5% vs 37.5%) and spleen (average ~44.8% vs 33.7%) (Figure 5c

and d). In contrast, CD19 was associated mostly with CD38<sup>+</sup>MHC-II<sup>+</sup> OT-I cells (mean 5.7% vs 29.4% in MLN and 5.6% vs 53.0% in spleen), while it was rarely detected on CD38<sup>-</sup>MHC-II<sup>+</sup> and no CD19 expression was observed on OT-I cells in BAL, suggesting that interaction of CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells with CD19<sup>+</sup> B cells via trogocytosis provides the source of MHC-II.

To further verify whether the expression of CD19, CD11c and MHC-II was intrinsic to OT-I cells, we measured CD19, CD11c and MHC-II (H2-Ab) mRNA



**Figure 5.** CD38<sup>+</sup> OT-I T cells do not intrinsically express MHC-II and acquire it via trogocytosis. C57BL/6 and MHC-II<sup>-/-</sup> mice ( $n = 4$  or  $5$ /group) received  $10^4$  OT-I T cells via the i.v. route 24 hours prior to infection with  $10^4$  PFU of X31-OVA. **(a)** Representative dot plots of CD38 and MHC-II presence on OT-I T cells in MLN, BAL and spleens 8 days p.i. **(b)** Bar graphs show the (i) number and (ii) frequency of CD38<sup>-</sup>MHC-II<sup>+</sup> and CD38<sup>+</sup>MHC-II<sup>+</sup> cells within the MHC-II<sup>+</sup> OT-I T cell pool in each organ. **(c)** Representative dot plots and histograms of CD11c and CD19 presence on CD38<sup>-</sup>MHC-II<sup>+</sup> (blue) and CD38<sup>+</sup>MHC-II<sup>+</sup> (green) OT-I T cells in C57BL/6 mice as well as **(d)** (i) their numbers and (ii) frequencies. The experiment was performed two times. Statistical analysis was performed using Sidak's multiple comparisons test.

levels in naïve, effector (10 d.p.i.) and memory (60 d.p.i.) CD8<sup>+</sup> T-cell populations following X31-OVA infection. Although gene expression of CD11c was not initially detected in naïve populations (Supplementary figure 5a; mean = 14.67), a  $2.4 \times 10^2$ -fold increase was observed in effector (Supplementary figure 5b; mean = 3494) and  $1.4 \times 10^2$ -fold increase in memory (Supplementary figure 5c; mean = 1985.5) CD8<sup>+</sup> T-cell populations, demonstrating that CD11c is intrinsic to CD8<sup>+</sup> T cells and upregulated as they differentiate. In contrast, this was not the case for CD19 and MHC-II (H2-Ab), with undetectable levels of gene expression observed in naïve, effector and memory CD8<sup>+</sup> T-cell populations, similar to levels observed for CD4 gene expression. Overall, our data support the notion that the surface presence of MHC-II on CD8<sup>+</sup> T cells is potentially acquired from B cells and dendritic cells/macrophages during influenza virus challenge.

### Superior recall capacity of CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells

To investigate the functional significance of CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells during IAV infection, we analysed the recall capacity of memory OT-I cells established from four subsets of day 8 effectors depicted by CD38 and MHC-II presence (CD38<sup>-</sup>MHC-II<sup>-</sup>, CD38<sup>+</sup>MHC-II<sup>-</sup>, CD38<sup>-</sup>MHC-II<sup>+</sup>, CD38<sup>+</sup>MHC-II<sup>+</sup>). OT-I cells adoptively transferred into B6 mice were expanded *in vivo* following infection with X31-OVA. On day 8 after infection, 4 populations of OT-I cells were FACS-isolated (Figure 6a). Each (CD38<sup>-</sup>MHC-II<sup>-</sup>, CD38<sup>+</sup>MHC-II<sup>-</sup>, CD38<sup>-</sup>MHC-II<sup>+</sup>, CD38<sup>+</sup>MHC-II<sup>+</sup>) population was adoptively transferred into separate naïve recipient B6 mice and subsequently rested for 30 days to establish memory formation. All mice were then challenged with X31-OVA virus. Mice that received CD38<sup>-</sup>MHC-II<sup>-</sup> OT-I cells



exhibited significantly ( $P < 0.05$ ) more body weight loss than mice that received OT-I cells expressing only CD38 (CD38<sup>+</sup>MHC-II<sup>-</sup>), MHC-II (CD38<sup>-</sup>MHC-II<sup>+</sup>) or both these markers (CD38<sup>+</sup>MHC-II<sup>+</sup>) (Figure 6b), indicating an important contribution of these activation markers for protection against severe IAV disease. Importantly, the greatest recall numbers of memory OT-I cells were observed in both the BAL (Figure 6ci and ii) and spleen (Figure 6ci and iii) of mice that received CD38<sup>+</sup>MHC-II<sup>+</sup> cells with OT-I numbers being ~3.1-fold and ~4.2-fold higher, respectively, when compared to other subsets.

Given that we observed the acquisition of MHC-II molecules by CD8<sup>+</sup> T cells during primary infection (Figure 5), we investigated whether this process also occurred following secondary challenge. Irrespective of the original phenotype of OT-I cells transferred, MHC-II<sup>+</sup> OT-I cells (mean range of 20.4–31.06% across four groups) were found in BAL (Figure 6di and ii). Furthermore, distinct populations of CD38<sup>+</sup>MHC-II<sup>+</sup> OT-I cells were detected in the spleens of mice across all four groups (Figure 6di and iii), indicating that OT-I cells that did not previously exhibit this phenotype can differentiate into CD38<sup>+</sup>MHC-II<sup>+</sup>-expressing cells upon rechallenge. This, however, did not improve their recall ability and highlights the importance of establishing CD38<sup>+</sup>MHC-II<sup>+</sup> phenotype prior to secondary exposure. Interestingly, while both CD19<sup>+</sup> and CD11c<sup>+</sup> OT-I cells could be found on CD38<sup>+</sup>MHC-II<sup>+</sup> OT-I cells in the spleens of all animal groups (Figure 6ei and iii), only CD19<sup>-</sup>CD11c<sup>+</sup> OT-I cells could be detected in BAL (Figure 6ei and ii). Overall, our findings highlight the importance of the CD38<sup>+</sup>MHC-II<sup>+</sup> phenotype for CD8<sup>+</sup> T-cell recall.


## DISCUSSION

Co-expression of CD38<sup>+</sup>MHC-II<sup>+</sup> on human CD8<sup>+</sup> T cells is a hallmark of viral-specific T cell responses during many viral infections. In particular, early and rapid expansion of CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells can correlate with effective viraemia control during acute HIV,<sup>20</sup> Ebola,<sup>12</sup> HCV<sup>31</sup> and Dengue<sup>16</sup> infection. Our previous studies in H7N9 patients in China showed that the earlier recruitment of activated CD8<sup>+</sup> T cells correlated with shorter duration of hospitalisation, while late recruitment of CD8<sup>+</sup> T cells leads to more diverse immune responses including upregulation of neutralising antibodies, CD4<sup>+</sup> T cells and NK cells.<sup>9</sup> While patients who recovered from H7N9 had early IFN- $\gamma$ -secreting CD8<sup>+</sup> T cells,<sup>10</sup> persistent

and prolonged expression of CD38 and MHC-II on CD8<sup>+</sup> T cells was associated with fatal outcomes.<sup>10</sup>

In this study, we demonstrate that IAV infection in a mouse model also induced the activation and expansion of CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells. The presence of CD38<sup>+</sup> and MHC-II<sup>+</sup> on CD8<sup>+</sup> T cells recalled following H7N9 challenge correlated with high levels of PD-1 expression in line with our observations in H7N9-infected patients who survived.<sup>10</sup> CD38<sup>+</sup>MHC-II<sup>+</sup>PD-1<sup>+</sup>CD8<sup>+</sup> T cells were also detected in the primary response following infection with the mouse adapted strain, X31. Of note, increased disease severity resulting from infection with a high dose of X31 was not only characterised by excessive cytokine production, reminiscent of early hypercytokinemia observed during fatal H7N9 infection in humans,<sup>9</sup> but also led to increased PD-1<sup>+</sup> expression in CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells. This is expected given that CD8<sup>+</sup> T-cell exhaustion, defined by PD-1<sup>high</sup> expression, is a notable feature of disease conditions where excessive or prolonged inflammatory conditions are present, such as during acute and chronic infections caused by highly virulent IAV strains,<sup>10</sup> HIV,<sup>32,33</sup> B type hepatitis (HBV)<sup>34</sup> and lymphocytic choriomeningitis virus (LCMV).<sup>35</sup>

Within the total primed CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T-cell population in mice following influenza virus infection, a large proportion appeared to be tetramer-negative, which indicates recruitment of bystander CD8<sup>+</sup> T cells at the site of infection. This was observed within populations of primary CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T-cell populations (Figure 3). This could be because of inflammation-induced expansion not only at the site of infection but also in peripheral immune organs as numerous studies show that cytokines<sup>36</sup> such as type I IFN,<sup>37</sup> IL-15<sup>38</sup> and IL-12/IL-18<sup>39</sup> are capable of recruiting non-virus-specific CD8<sup>+</sup> T cells during different infectious diseases. It is unclear, however, what impact these bystander CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells have on the overall immune response against IAV infection. Similar findings have been noted by researchers who found bystander CD8<sup>+</sup> T cells activated during the early phases of HIV-1 infection with CD38<sup>+</sup>MHC-II<sup>+</sup> phenotype and specificity for cytomegalovirus, Epstein–Barr virus and influenza antigens.<sup>20</sup> Moreover, bystander CD8<sup>+</sup> T cells and CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells can exhibit cytotoxic effects during acute hepatitis A virus infection closely correlating with severe liver injury.<sup>40</sup> Thus, while not much is known about the



**Figure 6.** Superior recall capacity of CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells. **(a)** Naïve OT-I cells ( $10^4$  per mouse) were transferred into C57BL/6 mice and the next day challenged with  $10^4$  PFU X31-OVA virus. OT-I cells (from MLN and spleen) were sorted based on CD38 and MHC-II presence on day 8 p.i. Sorted OT-I cells were adoptively transferred into new recipient C57BL/6 mice ( $5 \times 10^3$  cells per mice) and rested for 30 days. Mice were then challenged with  $10^4$  PFU X31-OVA virus and sacrificed on day 8 p.i. **(b)** Mice body weight were monitored over the course of 8 days following secondary viral challenge. **(c)** (i) Representative FACS plots gated on CD8<sup>+</sup> T cells across different recipient mice groups and showing the frequency of OT-I cells in BAL and spleen. Numbers of OT-I cells in (ii) BAL and (iii) spleen. **(d)** (i) Representative FACS plot for CD38 and MHC-II presence on OT-I cells from different recipient mice groups. Percentage of phenotypes based on CD38 and MHC-II of OT-I cells in (ii) BAL and (iii) spleen. **(e)** (i) Representative FACS plot for CD19 and CD11c presence on OT-I cells from different recipient mice groups. Percentage of phenotypes based on CD19 and CD11c of OT-I cells in (ii) BAL and (iii) spleen. The experiment was performed two times. Statistics comparing original body weight were performed using the unpaired *t*-test (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ). Statistics comparing OT-I cell numbers were performed using Sidak’s multiple comparisons test.

function of bystander CD38<sup>+</sup>MHC-II<sup>+</sup> CD8<sup>+</sup> T cells during influenza infection, it is possible that their presence may be related to the hypercytokinemia state at site of infection and contribute to lung damage leading to severe disease outcomes.<sup>9</sup> As previous studies suggest that trogocytosis of CD38 can occur during interaction between cells,<sup>41</sup> it is also possible that at least some level of CD38 expression could be acquired by trogocytosis.

In contrast to human CD8<sup>+</sup> T cells, murine CD8<sup>+</sup> T cells lack the transcription factor *CIITA*, a master regulator of *H2-Ab* (*MHC-II*) gene expression.<sup>26</sup> However, MHC-II is highly expressed on antigen-presenting cells (APCs) and our results are the first to demonstrate *in vivo* that CD38<sup>+</sup>CD8<sup>+</sup> T cells can 'snatch' MHC-II, along with CD19 and possibly other cell surface markers from B-cell populations. Trogocytosis of cell surface markers has been described for many immune cells in both mice and humans. For example, basophils can acquire MHC-II from dendritic cells to promote T-cell differentiation to Th2 cells.<sup>42</sup> Similarly, T cells can acquire HLA-G from APCs changing their function as effector cells to regulatory cells.<sup>43</sup> Of relevance, CD38 expressed on B cells can establish lateral associations with various membrane proteins/complexes, including CD19 to help mediate intracellular signalling.<sup>44</sup> The interaction of both these markers thus paints a plausible scenario where CD19 is 'snatched' from B cells via interaction with CD38 on CD8<sup>+</sup> T cells. Recent evidence also indicates that the exchange of markers between CD8<sup>+</sup> T-cell and B-cell populations is bidirectional. Strittmatter-Keller *et al.*<sup>45</sup> in particular have reported a population of human B cells expressing CD8 despite the absence of CD8 $\alpha$  or CD8 $\beta$  message, suggesting that this marker is acquired via cell-to-cell interactions with T cells. Although CD11c expression was detected on murine MHC-II<sup>+</sup>CD8<sup>+</sup> T cells in our study, it should be noted that murine CD8<sup>+</sup> T cells can express a certain level of CD11c intrinsically.

What is to be gained by CD38<sup>+</sup>CD8<sup>+</sup> T cells acquiring MHC-II presence? Our adoptive transfer results demonstrate that MHC-II on murine effector CD38<sup>+</sup>CD8<sup>+</sup> T cells plays a role in their optimal survival and expansion following secondary challenge. In fact, *in vitro* studies have shown that murine CD8<sup>+</sup> T cells that have acquired MHC-II molecules from dendritic cells are able to stimulate CD4<sup>+</sup> T cells in culture.<sup>46</sup> Given the importance of helper T cells in memory CD8<sup>+</sup> T cell formation<sup>47,48</sup> and in the recall of secondary responses,<sup>49,50</sup> it can be assumed that CD8<sup>+</sup> T cells

expressing MHC-II molecules can also present antigen for recognition by CD4<sup>+</sup> T cells to stimulate the secretion of cytokines that promote effector function and differentiation into memory populations. This could therefore constitute an additional mechanism to amplify T-helper responses<sup>51</sup> but may also contribute to excessive responses or even tolerance,<sup>52</sup> especially if immune-regulatory mechanisms are perturbed as reflected in dysfunctional innate immune responses observed during severe H7N9 infection.<sup>9</sup> Other implications can be gleaned from studies demonstrating snatching of peptide-MHC-I complexes (pMHC) by CD8<sup>+</sup> T cells from APCs via cell-cell interactions.<sup>29,53,54</sup> Here, trogocytosis can lead to fratricide of T cells or exhaustion because of prolonged engagement of TCRs with 'snatched' MHC-II-antigen complexes especially in the presence of high densities of pMHC.<sup>53</sup> These scenarios highlight the impact of trogocytosis of MHC-II molecules, enhancing interaction between CD4<sup>+</sup> and CD8<sup>+</sup> T cells to boost memory CD8<sup>+</sup> T-cell recall responses, but in the event of a severe viral infection, this process may impair CD8<sup>+</sup> T-cell responses as observed in patients with fatal H7N9.

## METHODS

### Ethics statement

Animal experiments were conducted according to the Australian National Health and Medical Research Council Code of Practice for the Care and Use of Animals for Scientific Purposes Guidelines for the housing and care of laboratory animals. Ethics was approved by the University of Melbourne Animal Ethics Experimentation Committee (1714108). Animal experiments involving H7N9 infection were approved by the Shanghai Public Health Clinical Center in China (2014-E032-01).

### Mice and viral infections

For primary infections, 6- to 8-week-old male or female C57BL/6 mice were lightly anaesthetised with isoflurane and infected by intranasal (i.n.) instillation (30  $\mu$ L) with 10<sup>2</sup> and 10<sup>5</sup> PFU of A/HK/x31 (X31; H3N2). To examine secondary CD8<sup>+</sup> T-cell responses in mice following H7N9 infection, mice were first primed i.n. with 10<sup>4</sup> EID<sub>50</sub> of A/Chicken/Shanghai/F/98 (H9N2) virus, followed 60 days later with 10<sup>6</sup> PFU of A/Shanghai/4664T/2013 (H7N9) virus.

To investigate mechanisms underlying MHC-II presence on murine CD8<sup>+</sup> T cells, 10<sup>4</sup> naïve OT-I cells were adoptively transferred into C57BL/6 mice or MHC-II<sup>-/-</sup> mice 24 h prior to infection with X31-OVA. After 8 days, CD45.1<sup>+</sup>CD8<sup>+</sup>V $\alpha$ 2<sup>+</sup> OT-I cells in the BAL, mediastinal lymph node and spleen were assessed. The experiment was repeated twice with 3–5 mice per group for each repeat.

To examine the recall ability of CD38<sup>+</sup>MHC-II<sup>+</sup>CD8<sup>+</sup> T cells, 10<sup>4</sup> naïve OT-I cells were adoptively transferred into C57BL/6 mice 24 h prior to infection with X31-OVA. After 8 days, CD45.1<sup>+</sup>CD8<sup>+</sup>V $\alpha$ 2<sup>+</sup> OT-I cells in the lymph node and spleen were four-way sorted based on their presence of CD38 and MHC-II. Each sorted population was adoptively transferred into separate naïve C57BL/6-recipient mice (5 × 10<sup>3</sup> cells per mouse) and 30 days later infected with X31-OVA. The experiment was repeated twice with 3–5 mice per group for each repeat.

## Tissue sampling and cell preparation

Lungs, spleens, mediastinal lymph nodes (MLN) and bronchoalveolar lavage (BAL) were collected from mice at various time points after infection. Lungs were either homogenised and centrifuged to obtain clarified supernatants to assay for viral titres or enzymatically digested in collagenase III (Worthington Biochemical Corporation, USA; 1 mg mL<sup>-1</sup>) and DNase I (Sigma-Aldrich, Germany; 0.5 mg mL<sup>-1</sup>) before passing through cell sieves to obtain single-cell suspensions for analysis. Where necessary, cell suspensions from tissues were incubated with 0.15 M NH<sub>4</sub>Cl and 17 mM Tris-HCl at pH 7.2 for 5 min at 37°C to lyse red blood cells.

## Measurement of lung viral load

Titres of infectious virus were determined by plaque assays on confluent Madin-Darby canine kidney (MDCK) cell monolayers cultured in six-well plates. Cells were infected with lung homogenate supernatants at varying dilutions for 45 min at 37°C before the addition of Leibovitz L15 or MEM medium containing 0.9% agarose overlay containing Trypsin (Worthington Biochemical, NJ, USA), as previously described.<sup>55</sup> Plates were incubated at 37°C 5% CO<sub>2</sub> for 3 days, and virus-mediated cell lysis then counted as plaques on the cell layer and expressed as plaque forming units (PFU).

## Analysis of cytokine levels

Cytokines present in lung homogenate supernatants were measured using a BD CBA flex set (BD Bioscience) as per the manufacturer's instructions.<sup>55</sup> Samples were analysed using a Becton Dickinson FACS Canto II flow cytometer. Data were analysed using FCAP Array software (Soft Flow Inc., Pecs, Hungary).

## Tetramer and antibody staining

MHC-I tetramer targeting the immunodominant epitope of the influenza nucleoprotein (D<sup>b</sup>NP<sub>366-374</sub> – ASNENMETM, D<sup>b</sup>PA<sub>224-233</sub> – SLENFRAYV) was produced in-house and conjugated to streptavidin-APC/PE (Life Technologies Australia Pty Ltd) at a 1:250 dilution at room temperature for 1h. Cells were stained with combinations of fluorochrome-conjugated antibodies: PerCP-Cy5.5-CD3 (#551163), PE-CD8 (#561095), BV421-I-Ab (#562928), APC-CD44 (#553133), FITC-CD44 (#553133), BV711-CD38 (#740697), PerCP-Cy5.5-CD8 (#551162), APC/eF780-CD62L (#47-0621-82), APC-CD11c (#17011481), PE-Cy7-TCR-va2

(#560624) from BD Biosciences, USA; and PE-Cy7-CD38 (#102718), BV785-PD-1 (#329908), APC-Cy7-CD45.1 (#110716), FITC-I-Ab (#116406), Pacific Blue-I-Ab (#116422), FITC-CD19 (#115506) from Biolegend, USA. AF700-CD3 (#56003382) was purchased from Invitrogen, USA.

Live/Dead-aqua 525 was purchased from Invitrogen. Briefly, cell suspensions were stained with Live/Dead Aqua viability dye at room temperature for 10 min followed by staining with tetramer for 15 min and cell surface marker antibodies for 30 min. Cells were fixed with 1% paraformaldehyde before analysis by flow cytometry. All antibody and tetramer staining was performed at 4°C and in the dark. Samples were subsequently acquired on a Becton Dickinson LSR Fortessa or Aria III flow cytometer and data analysed by FlowJo Software (Tree Star Inc., USA).

## RNA-Seq

The experiment described in Russ et al.<sup>56</sup> was reanalysed for this study. Briefly, RNA from sorted OT-I CTLs (~10<sup>6</sup>) at naïve, effector and memory stage, respectively, were extracted using TRIzol reagent and purified. RNA-seq libraries were then generated using Illumina's TruSeq RNA v2 sample preparation protocol according to manufacturers' instructions, which include cDNA synthesis and cDNA library preparation. PCR amplification on cDNA libraries was performed using Illumina HiSeq2000. RNA-Seq data were aligned to Mouse mm10 genome using HopHat (with Bowtie2) and further analysed using Bioconductor R package, edgeR Bioconductor package.

## Statistical analyses

The comparison between absolute numbers of cells was analysed using Tukey's or Sidak's multiple comparisons test. Body weight between mice groups was compared by unpaired *t*-tests. Absolute numbers of OT-I cells from different mice groups were compared using the Log-rank (Mantel-Cox) test.

## ACKNOWLEDGMENTS

The authors thank Professor SJ Turner for insightful discussions. This work was supported by the Australian National Health and Medical Research Council (NHMRC) Program Grant (#1071916) and NHMRC Investigator Grant (#1173871) to KK. XJ was a recipient of China Scholarship Council-UoM Joint Scholarship. SYC was a recipient of Melbourne Research Scholarship from University of Melbourne.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## AUTHOR CONTRIBUTIONS

**Xiaoxiao Jia:** Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Writing-original draft. **Brendon Y Chua:** Formal analysis; Investigation; Writing-original draft. **Liyan Loh:** Investigation;

Supervision; Writing-review & editing. **Marios Koutsakos**: Investigation; Writing-review & editing. **Lukasz Kedzierski**: Investigation; Writing-review & editing. **Moshe Olshansky**: Investigation; Writing-review & editing. **William R Heath**: Conceptualization; Writing-review & editing. **So Young Chang**: Data curation; Formal analysis; Writing-review & editing. **Jianqing Xu**: Conceptualization; Resources; Writing-review & editing. **Zhongfang Wang**: Conceptualization; Investigation; Supervision; Writing-review & editing. **Katherine Kedzierska**: Conceptualization; Project administration; Resources; Supervision; Writing-original draft.

## REFERENCES

1. Troeger CE, Blacker BF, Khalil IA et al. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med* 2019; **7**: 69–89.
2. Iuliano AD, Roguski KM, Chang HH et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *Lancet* 2018; **391**: 1285–1300.
3. Ungchusak K, Auewarakul P, Dowell SF et al. Probable person-to-person transmission of avian influenza A (H5N1). *N Engl J Med* 2005; **352**: 333–340.
4. Li Q, Zhou L, Zhou M et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. *N Engl J Med* 2014; **370**: 520–532.
5. Koutsakos M, Illing PT, Nguyen THO et al. Human CD8<sup>+</sup> T cell cross-reactivity across influenza A, B and C viruses. *Nat Immunol* 2019; **20**: 613–625.
6. McMichael AJ, Gotch FM, Noble GR, Beare PAS. Cytotoxic T-cell immunity to influenza. *N Engl J Med* 1983; **309**: 13–17.
7. Sridhar S, Begom S, Bermingham A et al. Cellular immune correlates of protection against symptomatic pandemic influenza. *Nat Med* 2013; **19**: 1305–1312.
8. Kreijtz JHCM, de Mutsert G, van Baalen CA, Fouchier RAM, Osterhaus ADME, Rimmelzwaan GF. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. *J Virol* 2008; **82**: 5161–5166.
9. Wang Z, Wan Y, Qiu C et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8<sup>+</sup> T cells. *Nat Commun* 2015; **6**: 1–12.
10. Wang Z, Zhu L, Nguyen THO et al. Clonally diverse CD38<sup>+</sup>HLA-DR<sup>+</sup>CD8<sup>+</sup> T cells persist during fatal H7N9 disease. *Nat Commun* 2018; **9**: 824.
11. Funaro A, Spagnoli GC, Ausiello CM et al. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. *J Immunol* 1990; **145**: 2390–2396.
12. Ruibal P, Oestereich L, Lütke A et al. Unique human immune signature of Ebola virus disease in Guinea. *Nature* 2016; **533**: 100–104.
13. Radziewicz H, Ibegbu CC, Hon H et al. Impaired hepatitis C virus (HCV)-specific effector CD8<sup>+</sup> T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. *J Virol* 2008; **82**: 9808–9822.
14. Hua S, Lécuroux C, Sáez-Cirión A et al. Potential role for HIV-specific CD38<sup>+</sup>/HLA-DR<sup>+</sup>CD8<sup>+</sup> T cells in viral suppression and cytotoxicity in HIV controllers. *PLoS One* 2014; **9**: 2–11.
15. Murray SM, Down CM, Boulware DR et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. *J Virol* 2010; **84**: 12082–12086.
16. Chandele A, Sewatanon J, Gunisetty S et al. Characterization of human CD8 T cell responses in Dengue virus-infected patients from India. *J Virol* 2016; **90**: 11259–11278.
17. Fox A, Le NMH, Horby P et al. Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. *PLoS One* 2012; **7**: e31535.
18. Thevarajan I, Nguyen THO, Koutsakos M et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. *Nat Med* 2020; **26**: 453–455.
19. Xu Z, Shi L, Wang Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020; **8**: 420–422.
20. Ndhlovu Z, Kanya P, Mewalal N et al. Magnitude and kinetics of CD8<sup>+</sup> T cell activation during hyperacute HIV infection impact viral set point. *Immunity* 2015; **43**: 591–604.
21. Lindgren T, Ahlm C, Mohamed N, Evander M, Ljunggren H-G, Björkström NK. Longitudinal analysis of the human T cell response during acute hantavirus infection. *J Virol* 2011; **85**: 10252–10260.
22. Miller JD, van der Most RG, Akondy RS et al. Human effector and memory CD8<sup>+</sup> T cell responses to smallpox and yellow fever vaccines. *Immunity* 2008; **28**: 710–722.
23. Ho HN, Hultin LE, Mitsuyasu RT et al. Circulating HIV-specific CD8<sup>+</sup> cytotoxic T cells express CD38 and HLA-DR antigens. *J Immunol* 1993; **150**: 3070–3079.
24. Sachdeva M, Fischl MA, Pahwa R, Sachdeva N, Pahwa S. Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. *JAIDS J Acquir Immune Defic Syndr* 2010; **54**: 447–454.
25. Cukalac T, Chadderton J, Zeng W et al. The influenza virus-specific CTL immunodominance hierarchy in mice is determined by the relative frequency of high-avidity T cells. *J Immunol* 2014; **192**: 4061–4068.
26. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. *Genes Dev* 2000; **14**: 1156–1166.
27. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). *Cell* 1993; **75**: 135–146.
28. Schooten E, Klous P, van den Elsen PJ, Holling TM. Lack of MHC-II expression in activated mouse T cells correlates with DNA methylation at the CIITA-PIII region. *Immunogenetics* 2005; **57**: 795–799.
29. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? *Nat Immunol* 2003; **4**: 815.

30. Richert LE, Rynda-Apple A, Harmsen AL et al. CD11c<sup>+</sup> cells primed with unrelated antigens facilitate an accelerated immune response to influenza virus in mice. *Eur J Immunol* 2014; **44**: 397–408.
31. Gruener NH, Lechner F, Jung M-C et al. Sustained dysfunction of antiviral CD8<sup>+</sup> T lymphocytes after infection with hepatitis C virus. *J Virol* 2001; **75**: 5550–5558.
32. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature* 2006; **443**: 350–354.
33. Tian X, Zhang A, Qiu C et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. *J Immunol* 2015; **194**: 3873–3882.
34. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. *Mol Immunol* 2008; **45**: 963–970.
35. Blackburn SD, Shin H, Haining WN et al. Coregulation of CD8<sup>+</sup> T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nat Immunol* 2009; **10**: 29–37.
36. Sckisel GD, Tietze JK, Zamora AE et al. Influenza infection results in local expansion of memory CD8<sup>+</sup> T cells with antigen non-specific phenotype and function. *Clin Exp Immunol* 2014; **175**: 79–91.
37. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. *Science* 1996; **272**: 1947–1950.
38. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8<sup>+</sup> T cells in vivo by IL-15. *Immunity* 1998; **8**: 591–599.
39. Chakir H, Lam DKY, Lemay AM, Webb JR. “Bystander polarization” of CD4<sup>+</sup> T cells: activation with high-dose IL-2 renders naive T cells responsive to IL-12 and/or IL-18 in the absence of TCR ligation. *Eur J Immunol* 2003; **33**: 1788–1798.
40. Kim J, Chang DY, Lee HW et al. Innate-like cytotoxic function of bystander-activated CD8<sup>+</sup> T cells is associated with liver injury in acute hepatitis A. *Immunity* 2018; **48**: 161–173.e5.
41. Krejcik J, van de Donk NWCJ. Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma. *Oncotarget* 2018; **9**: 33621–33622.
42. Miyake K, Shiozawa N, Nagao T, Yoshikawa S, Yamanishi Y, Karasuyama H. Trogocytosis of peptide–MHC class II complexes from dendritic cells confers antigen-presenting ability on basophils. *Proc Natl Acad Sci USA* 2017; **114**: 1111–1116.
43. LeMaout J, Caumartin J, Daouya M et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. *Blood* 2007; **109**: 2040–2048.
44. Deaglio S, Vaisitti T, Billington R et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. *Blood* 2007; **109**: 5390–5398.
45. Strittmatter-Keller U, Walter C, Rauld C et al. Fingerprints of CD8<sup>+</sup> T cells on human pre-plasma and memory B cells. *PLoS One* 2018; **13**: e0208187.
46. Romagnoli PA, Premenko-Lanier MF, Loria GD, Altman JD. CD8 T cell memory recall is enhanced by novel direct interactions with CD4 T cells enabled by MHC class II transferred from APCs. *PLoS One* 2013; **8**: e56999.
47. Novy P, Quigley M, Huang X, Yang Y. CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. *J Immunol* 2007; **179**: 8243–8251.
48. Sun JC, Williams MA, Bevan MJ. CD4<sup>+</sup> T cells are required for the maintenance, not programming, of memory CD8<sup>+</sup> T cells after acute infection. *Nat Immunol* 2004; **5**: 927–933.
49. Sun JC. Defective CD8 T cell memory following acute infection without CD4 T cell help. *Science* 2003; **300**: 339–342.
50. von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. *J Virol* 1996; **70**: 1072–1079.
51. Game DS, Rogers NJ, Lechler RI. Acquisition of HLA-DR and costimulatory molecules by T cells from allogeneic antigen presenting cells. *Am J Transplant* 2005; **5**: 1614–1625.
52. Helft J, Jacquet A, Joncker NT et al. Antigen-specific T-T interactions regulate CD4 T-cell expansion. *Blood* 2008; **112**: 1249–1258.
53. Huang J-F, Yang Y, Sepulveda H et al. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. *Science* 1999; **286**: 952.
54. Hudrisier D, Riond J, Mazarguil H, Gairin JE, Joly E. Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signaling-dependent manner. *J Immunol* 2001; **166**: 3645–3649.
55. van Wilgenburg B, Loh L, Chen Z et al. MAIT cells contribute to protection against lethal influenza infection in vivo. *Nat Commun* 2018; **9**: 4706.
56. Russ B, Olshansky M, Smallwood H et al. Distinct epigenetic signatures delineate transcriptional programs during virus-specific CD8<sup>+</sup> T cell differentiation. *Immunity* 2014; **41**: 853–865.

## Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.



This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.